Alex Thompson
Stock Analyst at Stifel
(1.76)
# 3,277
Out of 4,964 analysts
35
Total ratings
50%
Success rate
-4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $212 → $254 | $193.23 | +31.45% | 3 | Aug 8, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $7.94 | +177.25% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $42.26 | +30.15% | 1 | May 20, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $22 → $23 | $17.44 | +31.88% | 3 | May 2, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $9.65 | +273.06% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $30.40 | +97.37% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $15.20 | +222.37% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $707.96 | -29.37% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $17.13 | +215.24% | 2 | Mar 26, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $44 | $24.21 | +81.74% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $2.51 | -20.32% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $55.55 | +24.21% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.82 | -45.05% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $18.56 | +115.52% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $11.56 | +2,669.36% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $15.16 | +124.27% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.69 | +1,852.66% | 1 | Dec 14, 2022 |
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $212 → $254
Current: $193.23
Upside: +31.45%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $7.94
Upside: +177.25%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $42.26
Upside: +30.15%
Travere Therapeutics
May 2, 2025
Maintains: Hold
Price Target: $22 → $23
Current: $17.44
Upside: +31.88%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $9.65
Upside: +273.06%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $30.40
Upside: +97.37%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $15.20
Upside: +222.37%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $707.96
Upside: -29.37%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $17.13
Upside: +215.24%
Dianthus Therapeutics
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $24.21
Upside: +81.74%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $2.51
Upside: -20.32%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $55.55
Upside: +24.21%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.82
Upside: -45.05%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $18.56
Upside: +115.52%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $11.56
Upside: +2,669.36%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $15.16
Upside: +124.27%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.69
Upside: +1,852.66%